{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T06:24:41Z","timestamp":1782800681364,"version":"3.54.5"},"reference-count":132,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["EMIDDT"],"published-print":{"date-parts":[[2021,2,12]]},"abstract":"<jats:sec><jats:title\/><jats:p>Diabetic cardiomyopathy (DCM) is a significant complication of diabetes mellitus characterized by gradually failing heart with detrimental cardiac remodelings, such as fibrosis and diastolic and systolic dysfunction, which is not directly attributable to coronary artery disease. Insulin resistance and resulting hyperglycemia is the main trigger involved in the initiation of diabetic cardiomyopathy. There is a constellation of many pathophysiological events, such as lipotoxicity, oxidative stress, inflammation, inappropriate activation of the renin-angiotensin-aldosterone system, dysfunctional immune modulation promoting increased rate of cardiac cell injury, apoptosis, and necrosis, which ultimately culminates into interstitial fibrosis, cardiac stiffness, diastolic dysfunction, initially, and later systolic dysfunction too. These events finally lead to clinical heart failure of DCM. Herein, The pathophysiology of DCM is briefly discussed. Furthermore, potential therapeutic strategies currently used for DCM are also briefly mentioned.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1871530320666200731174724","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T16:56:38Z","timestamp":1596214598000},"page":"268-281","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Diabetic Cardiomyopathy: From Mechanism to Management in a Nutshell"],"prefix":"10.2174","volume":"21","author":[{"given":"Shahzad","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Pathophysiology, Wuhan University School of Medicine, Hubei, Wuhan,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed S.","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, Faculty of Engineering, Integral University, Lucknow,India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A.","family":"Kamal","sequence":"additional","affiliation":[{"name":"King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589,Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.bioorg.2019.02.009","volume":"86","author":"Abbas G.","year":"2019","unstructured":"Abbas G.; Al Harrasi A.; Hussain H.; Hamaed A.; Supuran C.T.; The management of diabetes mellitus-imperative role of natural products against dipeptidyl peptidase-4, \u03b1-glucosidase and sodium-dependent glucose co-transporter 2 (SGLT2). Bioorg Chem 2019,86,305-315","journal-title":"Bioorg Chem"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.phymed.2012.09.009","volume":"20","author":"Bharti S.K.","year":"2012","unstructured":"Bharti S.K.; Krishnan S.; Kumar A.; Rajak K.K.; Murari K.; Bharti B.K.; Gupta A.K.; Antihyperglycemic activity with DPP-IV inhibition of alkaloids from seed extract of Castanospermum australe: Investigation by experimental validation and molecular docking. Phytomedicine 2012,20(1),24-31","journal-title":"Phytomedicine"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1542\/pir.29-12-431","volume":"29","author":"Cooke D.W.","year":"2008","unstructured":"Cooke D.W.; Plotnick L.; Management of diabetic ketoacidosis in children and adolescents. Pediatr Rev 2008,29(12),431-435","journal-title":"Pediatr Rev"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3389\/fphar.2017.00228","volume":"8","author":"Chen G.","year":"2017","unstructured":"Chen G.; Guo M.; Rapid screening for \u03b1-Glucosidase inhibitors from Gymnema sylvestre by affinity ultrafiltration-HPLC-MS. Front Pharmacol 2017,8,228","journal-title":"Front Pharmacol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.fitote.2019.02.033","volume":"134","author":"He J-H.","year":"2019","unstructured":"He J-H.; Chen L-X.; Li H.; Progress in the discovery of naturally occurring anti-diabetic drugs and in the identification of their molecular targets. Fitoterapia 2019,134,270-289","journal-title":"Fitoterapia"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","volume":"57","author":"Bugger H.","year":"2014","unstructured":"Bugger H.; Abel E.D.; Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014,57(4),660-671","journal-title":"Diabetologia"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nrendo.2015.216","volume":"12","author":"Jia G.","year":"2016","unstructured":"Jia G.; DeMarco V.G.; Sowers J.R.; Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol 2016,12(3),144-153","journal-title":"Nat Rev Endocrinol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4239\/wjd.v4.i5.177","volume":"4","author":"Pappachan J.M.","year":"2013","unstructured":"Pappachan J.M.; Varughese G.I.; Sriraman R.; Arunagirinathan G.; Diabetic cardiomyopathy: pathophysiology, diagnostic evaluation and management. World J Diabetes 2013,4(5),177-189","journal-title":"World J Diabetes"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3390\/nu9111176","volume":"9","author":"Yoon M-S.","year":"2017","unstructured":"Yoon M-S.; The role of mammalian target of rapamycin (mTOR) in insulin signaling. Nutrients 2017,9(11),1176","journal-title":"Nutrients"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1161\/HYPERTENSIONAHA.115.06015","volume":"66","author":"Jia G.","year":"2015","unstructured":"Jia G.; Habibi J.; DeMarco V.G.; Martinez-Lemus L.A.; Ma L.; Whaley-Connell A.T.; Endothelial mineralocorticoid receptor deletion prevents diet-induced cardiac diastolic dysfunction in females. Hypertension 2015,66(6),1159-1167","journal-title":"Hypertension"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"E201","DOI":"10.1152\/ajpendo.00497.2011","volume":"302","author":"Kim J.A.","year":"2012","unstructured":"Kim J.A.; Jang H-J.; Martinez-Lemus L.A.; Sowers J.R.; Activation of mTOR\/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am J Physiol Endocrinol Metab 2012,302(2),E201-E208","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.107.728550","volume":"117","author":"van Heerebeek L.","year":"2008","unstructured":"van Heerebeek L.; Hamdani N.; Handoko M.L.; Falcao-Pires I.; Musters R.J.; Kupreishvili K.; Ijsselmuiden A.J.; Schalkwijk C.G.; Bronzwaer J.G.; Diamant M.; Borb\u00e9ly A.; van der Velden J.; Stienen G.J.; Laarman G.J.; Niessen H.W.; Paulus W.J.; Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008,117(1),43-51","journal-title":"Circulation"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.ahj.2015.08.008","volume":"170","author":"Lazo M.","year":"2015","unstructured":"Lazo M.; Halushka M.K.; Shen L.; Maruthur N.; Rebholz C.M.; Rawlings A.M.; Hoogeveen R.C.; Brinkley T.E.; Ballantyne C.M.; Astor B.C.; Selvin E.; Soluble receptor for advanced glycation end products and the risk for incident heart failure: The atherosclerosis risk in communities study. Am Heart J 2015,170(5),961-967","journal-title":"Am Heart J"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1111\/j.1582-4934.2008.00547.x","volume":"13","author":"Ma H.","year":"2009","unstructured":"Ma H.; Li S.Y.; Xu P.; Babcock S.A.; Dolence E.K.; Brownlee M.; Li J.; Ren J.; Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy. J Cell Mol Med 2009,13(8B),1751-1764","journal-title":"J Cell Mol Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"C593","DOI":"10.1152\/ajpcell.00069.2015","volume":"309","author":"Makino A.","year":"2015","unstructured":"Makino A.; Dai A.; Han Y.; Youssef K.D.; Wang W.; Donthamsetty R.; Scott B.T.; Wang H.; Dillmann W.H.; O-GlcNAcase overexpression reverses coronary endothelial cell dysfunction in type 1 diabetic mice. Am J Physiol Cell Physiol 2015,309(9),C593-C599","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1161\/01.RES.0000165478.06813.58","volume":"96","author":"Hu Y.","year":"2005","unstructured":"Hu Y.; Belke D.; Suarez J.; Swanson E.; Clark R.; Hoshijima M.; Dillmann W.H.; Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart. Circ Res 2005,96(9),1006-1013","journal-title":"Circ Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12929-016-0309-5","volume":"24","author":"Lee T-W.","year":"2017","unstructured":"Lee T-W.; Bai K-J.; Lee T-I.; Chao T-F.; Kao Y-H.; Chen Y-J.; PPARs modulate cardiac metabolism and mitochondrial function in diabetes. J Biomed Sci 2017,24(1),5","journal-title":"J Biomed Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1172\/JCI0214080","volume":"109","author":"Finck B.N.","year":"2002","unstructured":"Finck B.N.; Lehman J.J.; Leone T.C.; Welch M.J.; Bennett M.J.; Kovacs A.; Han X.; Gross R.W.; Kozak R.; Lopaschuk G.D.; Kelly D.P.; The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002,109(1),121-130","journal-title":"J Clin Invest"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"E923","DOI":"10.1152\/ajpendo.00360.2002","volume":"284","author":"Atkinson L.L.","year":"2003","unstructured":"Atkinson L.L.; Kozak R.; Kelly S.E.; Onay Besikci A.; Russell J.C.; Lopaschuk G.D.; Potential mechanisms and consequences of cardiac triacylglycerol accumulation in insulin-resistant rats. Am J Physiol Endocrinol Metab 2003,284(5),E923-E930","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"266","DOI":"10.4070\/kcj.2015.45.4.266","volume":"45","author":"Yilmaz S.","year":"2015","unstructured":"Yilmaz S.; Canpolat U.; Aydogdu S.; Abboud H.E.; Diabetic cardiomyopathy; summary of 41 years. Korean Circ J 2015,45(4),266-272","journal-title":"Korean Circ J"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175009","volume":"12","author":"Song C.","year":"2017","unstructured":"Song C.; Luo B.; Gong L.; Resveratrol reduces the apoptosis induced by cigarette smoke extract by upregulating MFN2. PLoS One 2017,12(4)","journal-title":"PLoS One"},{"key":"ref=22","author":"Yi C.","year":"2011","unstructured":"Yi C.; Vakifahmetoglu-Norberg H.; Yuan J.; Integration of apoptosis and metabolism Cold Spring Harbor symposia on quantitative biology 2011","journal-title":"Integration of apoptosis and metabolism Cold Spring Harbor symposia on quantitative biology"},{"key":"ref=23","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9583268","author":"Xia P.","year":"2016","unstructured":"Xia P.; Liu Y.; Cheng Z.; Signaling pathways in cardiac myocyte apoptosis. BioMed Res Int 2016","journal-title":"BioMed Res Int"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1161\/01.RES.82.11.1111","volume":"82","author":"Haunstetter A.","year":"1998","unstructured":"Haunstetter A.; Izumo S.; Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res 1998,82(11),1111-1129","journal-title":"Circ Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1161\/CIRCRESAHA.110.225730","volume":"108","author":"Kung G.","year":"2011","unstructured":"Kung G.; Konstantinidis K.; Kitsis R.N.; Programmed necrosis, not apoptosis, in the heart. Circ Res 2011,108(8),1017-1036","journal-title":"Circ Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/BF00403325","volume":"33","author":"Takahashi K.","year":"1990","unstructured":"Takahashi K.; Ghatei M.A.; Lam H-C.; O\u2019Halloran D.J.; Bloom S.R.; Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990,33(5),306-310","journal-title":"Diabetologia"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/sj.bjp.0701704","volume":"123","author":"Makino A.","year":"1998","unstructured":"Makino A.; Kamata K.; Elevated plasma endothelin-1 level in streptozotocin-induced diabetic rats and responsiveness of the mesenteric arterial bed to endothelin-1. Br J Pharmacol 1998,123(6),1065-1072","journal-title":"Br J Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0895-7061(02)03060-1","volume":"15","author":"Schneider J.G.","year":"2002","unstructured":"Schneider J.G.; Tilly N.; Hierl T.; Sommer U.; Hamann A.; Dugi K.; Leidig-Bruckner G.; Kasperk C.; Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens 2002,15(11),967-972","journal-title":"Am J Hypertens"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S0140-6736(95)91504-4","volume":"346","author":"Kiowski W.","year":"1995","unstructured":"Kiowski W.; S\u00fctsch G.; Hunziker P.; M\u00fcller P.; Kim J.; Oechslin E.; Schmitt R.; Jones R.; Bertel O.; Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995,346(8977),732-736","journal-title":"Lancet"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/01.CIR.0000140766.52771.6D","volume":"110","author":"Xu F.P.","year":"2004","unstructured":"Xu F.P.; Chen M.S.; Wang Y.Z.; Yi Q.; Lin S.B.; Chen A.F.; Luo J.D.; Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 2004,110(10),1269-1275","journal-title":"Circulation"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bbalip.2010.11.002","volume":"1811","author":"Alvarez-Guardia D.","year":"2011","unstructured":"Alvarez-Guardia D.; Palomer X.; Coll T.; Serrano L.; Rodr\u00edguez-Calvo R.; Davidson M.M.; Merlos M.; El Kochairi I.; Michalik L.; Wahli W.; V\u00e1zquez-Carrera M.; PPAR\u03b2\/\u03b4 activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. Biochim Biophys Acta 2011,1811(2),59-67","journal-title":"Biochim Biophys Acta"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1161\/CIRCULATIONAHA.110.938217","volume":"121","author":"Widyantoro B.","year":"2010","unstructured":"Widyantoro B.; Emoto N.; Nakayama K.; Anggrahini D.W.; Adiarto S.; Iwasa N.; Yagi K.; Miyagawa K.; Rikitake Y.; Suzuki T.; Kisanuki Y.Y.; Yanagisawa M.; Hirata K.; Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 2010,121(22),2407-2418","journal-title":"Circulation"},{"key":"ref=33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104771","volume":"9","author":"Luo B.","year":"2014","unstructured":"Luo B.; Li B.; Wang W.; Liu X.; Xia Y.; Zhang C.; Zhang M.; Zhang Y.; An F.; NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS One 2014,9(8)","journal-title":"PLoS One"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1080\/15548627.2015.1051295","volume":"11","author":"Kanamori H.","year":"2015","unstructured":"Kanamori H.; Takemura G.; Goto K.; Tsujimoto A.; Mikami A.; Ogino A.; Watanabe T.; Morishita K.; Okada H.; Kawasaki M.; Seishima M.; Minatoguchi S.; Autophagic adaptations in diabetic cardiomyopathy differ between type 1 and type 2 diabetes. Autophagy 2015,11(7),1146-1160","journal-title":"Autophagy"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.numecd.2018.06.005","volume":"28","author":"Feidantsis K.","year":"2018","unstructured":"Feidantsis K.; Mellidis K.; Galatou E.; Sinakos Z.; Lazou A.; Treatment with crocin improves cardiac dysfunction by normalizing autophagy and inhibiting apoptosis in STZ-induced diabetic cardiomyopathy. Nutr Metab Cardiovasc Dis 2018,28(9),952-961","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ijcard.2016.02.095","volume":"210","author":"Deluyker D.","year":"2016","unstructured":"Deluyker D.; Ferferieva V.; Noben J.P.; Swennen Q.; Bronckaers A.; Lambrichts I.; Rigo J.M.; Bito V.; Cross-linking versus RAGE: how do high molecular weight advanced glycation products induce cardiac dysfunction? Int J Cardiol 2016,210,100-108","journal-title":"Int J Cardiol"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7555\/JBR.31.20160116","volume":"32","author":"Zha Z.M.","year":"2018","unstructured":"Zha Z.M.; Wang J.H.; Li S.L.; Guo Y.; Pitavastatin attenuates AGEs-induced mitophagy via inhibition of ROS generation in the mitochondria of cardiomyocytes. J Biomed Res 2018,32(4),281-287","journal-title":"J Biomed Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2147\/VHRM.S11681","volume":"6","author":"Voulgari C.","year":"2010","unstructured":"Voulgari C.; Papadogiannis D.; Tentolouris N.; Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Health Risk Manag 2010,6,883-903","journal-title":"Vasc Health Risk Manag"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1161\/CIRCRESAHA.109.199810","volume":"105","author":"St\u00f8len T.O.","year":"2009","unstructured":"St\u00f8len T.O.; H\u00f8ydal M.A.; Kemi O.J.; Catalucci D.; Ceci M.; Aasum E.; Larsen T.; Rolim N.; Condorelli G.; Smith G.L.; Wisl\u00f8ff U.; Interval training normalizes cardiomyocyte function, diastolic Ca2+ control, and SR Ca2+ release synchronicity in a mouse model of diabetic cardiomyopathy. Circ Res 2009,105(6),527-536","journal-title":"Circ Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1139\/cjpp-2012-0294","volume":"91","author":"Epp R.A.","year":"2013","unstructured":"Epp R.A.; Susser S.E.; Morissette M.P.; Kehler D.S.; Jassal D.S.; Duhamel T.A.; Exercise training prevents the development of cardiac dysfunction in the low-dose streptozotocin diabetic rats fed a high-fat diet. Can J Physiol Pharmacol 2013,91(1),80-89","journal-title":"Can J Physiol Pharmacol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1590\/S0100-40422002000300016","volume":"25","author":"Maciel M.A.M.","year":"2002","unstructured":"Maciel M.A.M.; Pinto A.C.; Veiga V.F.; Grynberg N.F.; Echevarria A.; Plantas medicinais: a necessidade de Estudos multidisciplinares. Quim Nova 2002,25(3),429-438","journal-title":"Quim Nova"},{"key":"ref=42","first-page":"113","volume":"67","author":"Malviya N.","year":"2010","unstructured":"Malviya N.; Jain S.; Malviya S.; Antidiabetic potential of medicinal plants. Acta Pol Pharm 2010,67(2),113-118","journal-title":"Acta Pol Pharm"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1055\/s-2002-32894","volume":"68","author":"Verspohl E.J.","year":"2002","unstructured":"Verspohl E.J.; Recommended testing in diabetes research. Planta Med 2002,68(7),581-590","journal-title":"Planta Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/aps.2012.90","volume":"33","author":"Jiang C-S.","year":"2012","unstructured":"Jiang C-S.; Liang L.F.; Guo Y.W.; Natural products possessing protein tyrosine phosphatase 1B (PTP1B) inhibitory activity found in the last decades. Acta Pharmacol Sin 2012,33(10),1217-1245","journal-title":"Acta Pharmacol Sin"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.3390\/molecules23123334","volume":"23","author":"Ezzat S.M.","year":"2018","unstructured":"Ezzat S.M.; Bishbishy M.H.E.; Habtemariam S.; Salehi B.; Sharifi-Rad M.; Martins N.; Sharifi-Rad J.; Looking at marine-derived bioactive molecules as upcoming anti-diabetic agents: a special emphasis on PTP1B inhibitors. Molecules 2018,23(12),3334","journal-title":"Molecules"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/ajcn\/nqy083","volume":"108","author":"Rienks J.","year":"2018","unstructured":"Rienks J.; Barbaresko J.; Oluwagbemigun K.; Schmid M.; N\u00f6thlings U.; Polyphenol exposure and risk of type 2 diabetes: dose-response meta-analyses and systematic review of prospective cohort studies. Am J Clin Nutr 2018,108(1),49-61","journal-title":"Am J Clin Nutr"},{"key":"ref=47","first-page":"143","volume":"Vol. 1","author":"Unnikrishnan M.K.","year":"2014","unstructured":"Unnikrishnan M.K.; Veerapur V.; Nayak Y.; Mudgal P.P.; Mathew G.; Antidiabetic, Antihyperlipidemic and Antioxidant Effects of the Flavonoids: Polyphenols in Human Health and Disease; Ronald Ross Watson, Victor R Preedy, Sherma Zibadi 2014,Vol. 1,143-161","journal-title":"Antidiabetic, Antihyperlipidemic and Antioxidant Effects of the Flavonoids: Polyphenols in Human Health and Disease; Ronald Ross Watson, Victor R Preedy, Sherma Zibadi"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ejps.2009.09.004","volume":"38","author":"Sharma A.K.","year":"2009","unstructured":"Sharma A.K.; Srinivasan B.P.; Triple versus glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats. Eur J Pharm Sci 2009,38(5),433-444","journal-title":"Eur J Pharm Sci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jams.2012.10.005","volume":"6","author":"Thilagam E.","year":"2013","unstructured":"Thilagam E.; Parimaladevi B.; Kumarappan C.; Mandal S.C.; \u03b1-Glucosidase and \u03b1-amylase inhibitory activity of Senna surattensis. J Acupunct Meridian Stud 2013,6(1),24-30","journal-title":"J Acupunct Meridian Stud"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2174\/092986706776360860","volume":"13","author":"Jung M.","year":"2006","unstructured":"Jung M.; Park M.; Lee H.C.; Kang Y-H.; Kang E.S.; Kim S.K.; Antidiabetic agents from medicinal plants. Curr Med Chem 2006,13(10),1203-1218","journal-title":"Curr Med Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-0-387-87687-0_8","author":"La Greca A.M.","year":"2009","unstructured":"La Greca A.M.; Mackey E.R.; Behavioral Approaches to Chronic Disease in Adolescence 2009,85-100","journal-title":"Behavioral Approaches to Chronic Disease in Adolescence"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jtumed.2016.02.001","volume":"11","author":"Alhadramy M.S.","year":"2016","unstructured":"Alhadramy M.S.; Diabetes and oral therapies: A review of oral therapies for diabetes mellitus. J Taibah Univ Sci 2016,11(4),317-329","journal-title":"J Taibah Univ Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fendo.2017.00006","volume":"8","author":"Chaudhury A.","year":"2017","unstructured":"Chaudhury A.; Duvoor C.; Reddy Dendi V.S.; Kraleti S.; Chada A.; Ravilla R.; Marco A.; Shekhawat N.S.; Montales M.T.; Kuriakose K.; Sasapu A.; Beebe A.; Patil N.; Musham C.K.; Lohani G.P.; Mirza W.; Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne) 2017,8,6","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/s0031-9422(02)00104-8","volume":"60","author":"Ali M.S.","year":"2002","unstructured":"Ali M.S.; Jahangir M.; Hassan S.S.; Inhibition of alpha-glucosidase by oleanolic acid and its synthetic derivatives. Phytochemistry 2002,60(3),295-299","journal-title":"Phytochemistry"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3177\/jnsv.52.149","volume":"52","author":"Tadera K.","year":"2006","unstructured":"Tadera K.; Minami Y.; Takamatsu K.; Matsuoka T.; Inhibition of alpha-glucosidase and alpha-amylase by flavonoids. J Nutr Sci Vitaminol (Tokyo) 2006,52(2),149-153","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1078\/0944-7113-00065","volume":"9","author":"Ye F.","year":"2002","unstructured":"Ye F.; Shen Z.; Xie M.; Alpha-glucosidase inhibition from a Chinese medical herb (Ramulus mori) in normal and diabetic rats and mice. Phytomedicine 2002,9(2),161-166","journal-title":"Phytomedicine"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1479164112441524","volume":"9","author":"Standl E.","year":"2012","unstructured":"Standl E.; Schnell O.; Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation. Diab Vasc Dis Res 2012,9(3),163-169","journal-title":"Diab Vasc Dis Res"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"30003","DOI":"10.1016\/j.tcm.2019.12.010","volume":"S1050-1738","author":"Kato E.T.","year":"2020","unstructured":"Kato E.T.; Das S.R.; McGuire D.K.; Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions. Trends Cardiovasc Med 2020,S1050-1738(20),30003-7","journal-title":"Trends Cardiovasc Med"},{"key":"ref=59","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/281078","author":"Elya B.","year":"2012","unstructured":"Elya B.; Basah K.; Mun\u2019im A.; Yuliastuti W.; Bangun A.; Septiana E.K.; Screening of \u03b1-glucosidase inhibitory activity from some plants of apocynaceae, clusiaceae, euphorbiaceae, and rubiaceae. J Biomed Biotechnol 2012","journal-title":"J Biomed Biotechnol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/14756360802610761","volume":"24","author":"Al-masri I.M.","year":"2009","unstructured":"Al-masri I.M.; Mohammad M.K.; Tahaa M.O.; Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. J Enzyme Inhib Med Chem 2009,24(5),1061-1066","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=61","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/479505","volume":"2013","author":"Fan J.","year":"2013","unstructured":"Fan J.; Johnson M.H.; Lila M.A.; Yousef G.; de Mejia E.G.; Berry and citrus phenolic compounds inhibit dipeptidyl peptidase IV: implications in diabetes management. Evid Based Complement Alternat Med 2013,2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.dsx.2018.08.012","volume":"13","author":"Almagthali A.G.","year":"2019","unstructured":"Almagthali A.G.; Alkhaldi E.H.; Alzahrani A.S.; Alghamdi A.K.; Alghamdi W.Y.; Kabel A.M.; Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer. Diabetes Metab Syndr 2019,13(1),36-39","journal-title":"Diabetes Metab Syndr"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"38317","DOI":"10.1074\/jbc.M505853200","volume":"280","author":"Li X.","year":"2005","unstructured":"Li X.; Hansen P.A.; Xi L.; Chandraratna R.A.S.; Burant C.F.; Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor gamma and retinoic acid X receptors. J Biol Chem 2005,280(46),38317-38327","journal-title":"J Biol Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1053\/meta.2001.27202","volume":"50","author":"Kramer D.","year":"2001","unstructured":"Kramer D.; Shapiro R.; Adler A.; Bush E.; Rondinone C.M.; Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism 2001,50(11),1294-1300","journal-title":"Metabolism"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bcp.2014.07.018","volume":"92","author":"Wang L.","year":"2014","unstructured":"Wang L.; Waltenberger B.; Pferschy-Wenzig E-M.; Blunder M.; Liu X.; Malainer C.; Blazevic T.; Schwaiger S.; Rollinger J.M.; Heiss E.H.; Schuster D.; Kopp B.; Bauer R.; Stuppner H.; Dirsch V.M.; Atanasov A.G.; Natural product agonists of peroxisome proliferator-activated receptor gamma (PPAR\u03b3): a review. Biochem Pharmacol 2014,92(1),73-89","journal-title":"Biochem Pharmacol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1358\/dnp.2002.15.3.840011","volume":"15","author":"Guan Y.","year":"2002","unstructured":"Guan Y.; Zhang Y.; Breyer M.D.; The Role of PPARs in the Transcriptional control of cellular processes. Drug News Perspect 2002,15(3),147-154","journal-title":"Drug News Perspect"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.2337\/diabetes.54.8.2460","volume":"54","author":"Staels B.","year":"2005","unstructured":"Staels B.; Fruchart J-C.; Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005,54(8),2460-2470","journal-title":"Diabetes"},{"key":"ref=68","first-page":"583","volume":"15","author":"Gu M-X.","year":"2013","unstructured":"Gu M-X.; Liu X-C.; Jiang L.; [Effect of peroxisome proliferator-activated receptor-gamma on proliferation of airway smooth muscle cells in mice with asthma] Zhongguo Dang Dai Er Ke Za Zhi 2013,15(7),583-587","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s10554-011-9938-7","volume":"28","author":"Aboukhoudir F.","year":"2012","unstructured":"Aboukhoudir F.; Rekik S.; Left ventricular systolic function deterioration during dobutamine stress echocardiography as an early manifestation of diabetic cardiomyopathy and reversal by optimized therapeutic approach. Int J Cardiovasc Imaging 2012,28(6),1329-1339","journal-title":"Int J Cardiovasc Imaging"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jacc.2005.08.061","volume":"47","author":"Chung J.","year":"2006","unstructured":"Chung J.; Abraszewski P.; Yu X.; Liu W.; Krainik A.J.; Ashford M.; Caruthers S.D.; McGill J.B.; Wickline S.A.; Paradoxical increase in ventricular torsion and systolic torsion rate in type I diabetic patients under tight glycemic control. J Am Coll Cardiol 2006,47(2),384-390","journal-title":"J Am Coll Cardiol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.2337\/db10-0351","volume":"60","author":"Xie Z.","year":"2011","unstructured":"Xie Z.; Lau K.; Eby B.; Lozano P.; He C.; Pennington B.; Li H.; Rathi S.; Dong Y.; Tian R.; Kem D.; Zou M.H.; Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 2011,60(6),1770-1778","journal-title":"Diabetes"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s11897-011-0070-8","volume":"8","author":"Bibra H.v.","year":"2011","unstructured":"Bibra H.v.; Sutton M.S.J.; Impact of diabetes on postinfarction heart failure and left ventricular remodeling. Curr Heart Fail Rep 2011,8(4),242-251","journal-title":"Curr Heart Fail Rep"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/eurjhf\/hfs106","volume":"14","author":"Wong A.K.","year":"2012","unstructured":"Wong A.K.; Symon R.; AlZadjali M.A.; Ang D.S.; Ogston S.; Choy A.; Petrie J.R.; Struthers A.D.; Lang C.C.; The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. Eur J Heart Fail 2012,14(11),1303-1310","journal-title":"Eur J Heart Fail"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.cardfail.2010.05.027","volume":"16","author":"Mamas M.A.","year":"2010","unstructured":"Mamas M.A.; Deaton C.; Rutter M.K.; Yuille M.; Williams S.G.; Ray S.G.; New J.; Gibson J.M.; Neyses L.; Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated? J Card Fail 2010,16(9),761-768","journal-title":"J Card Fail"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.2337\/db07-0924","volume":"57","author":"Caglayan E.","year":"2008","unstructured":"Caglayan E.; Stauber B.; Collins A.R.; Lyon C.J.; Yin F.; Liu J.; Differential roles of cardiomyocyte and macrophage PPAR\u03b3 in cardiac fibrosis. Diabetes 2008,57(9),2470-2479","journal-title":"Diabetes"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.numecd.2008.09.002","volume":"19","author":"Sacc\u00e0 L.","year":"2009","unstructured":"Sacc\u00e0 L.; Napoli R.; Insulin resistance in chronic heart failure: a difficult bull to take by the horns. Nutr Metab Cardiovasc Dis 2009,19(5),303-305","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jacc.2014.04.083","volume":"64","author":"Doehner W.","year":"2014","unstructured":"Doehner W.; Frenneaux M.; Anker S.D.; Metabolic impairment in heart failure: the myocardial and systemic perspective. J Am Coll Cardiol 2014,64(13),1388-1400","journal-title":"J Am Coll Cardiol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"C508","DOI":"10.1152\/ajpcell.00248.2012","volume":"304","author":"Younce C.W.","year":"2013","unstructured":"Younce C.W.; Burmeister M.A.; Ayala J.E.; Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. Am J Physiol Cell Physiol 2013,304(6),C508-C518","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/1479164114559852","volume":"12","author":"Inzucchi S.E.","year":"2015","unstructured":"Inzucchi S.E.; Zinman B.; Wanner C.; Ferrari R.; Fitchett D.; Hantel S.; Espadero R.M.; Woerle H.J.; Broedl U.C.; Johansen O.E.; SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 2015,12(2),90-100","journal-title":"Diab Vasc Dis Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"Zinman B.","year":"2015","unstructured":"Zinman B.; Wanner C.; Lachin J.M.; Fitchett D.; Bluhmki E.; Hantel S.; Mattheus M.; Devins T.; Johansen O.E.; Woerle H.J.; Broedl U.C.; Inzucchi S.E.; Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015,373(22),2117-2128","journal-title":"N Engl J Med"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/1475-2840-12-169","volume":"12","author":"Yong Q.C.","year":"2013","unstructured":"Yong Q.C.; Thomas C.M.; Seqqat R.; Chandel N.; Baker K.M.; Kumar R.; Angiotensin type 1a receptor-deficient mice develop diabetes-induced cardiac dysfunction, which is prevented by renin-angiotensin system inhibitors. Cardiovasc Diabetol 2013,12(1),169","journal-title":"Cardiovasc Diabetol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.euje.2006.09.005","volume":"8","author":"Symeonides P.","year":"2007","unstructured":"Symeonides P.; Koulouris S.; Vratsista E.; Triantafyllou K.; Ioannidis G.; Thalassinos N.; Katritsis D.; Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study. Eur J Echocardiogr 2007,8(6),480-486","journal-title":"Eur J Echocardiogr"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1023\/B:MCBI.0000028765.89855.73","volume":"261","author":"Machackova J.","year":"2004","unstructured":"Machackova J.; Liu X.; Lukas A.; Dhalla N.S.; Renin-angiotensin blockade attenuates cardiac myofibrillar remodelling in chronic diabetes. Mol Cell Biochem 2004,261(1-2),271-278","journal-title":"Mol Cell Biochem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1758-5996-3-4","volume":"3","author":"Mohamad H.E.","year":"2011","unstructured":"Mohamad H.E.; Askar M.E.; Hafez M.M.; Management of cardiac fibrosis in diabetic rats; the role of peroxisome proliferator activated receptor gamma (PPAR-gamma) and calcium channel blockers (CCBs). Diabetol Metab Syndr 2011,3(1),4","journal-title":"Diabetol Metab Syndr"},{"key":"ref=85","first-page":"310","volume":"9","author":"Isidori A.","year":"2012","unstructured":"Isidori A.; Giannetta E.; Galea N.; Iacopo C.; Mandosi E.; Morano S.; Chronic inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy exerting an anti-remodeling effect: a randomized, controlled clinical trial with magnetic resonance imaging: ps-04-002. J Sex Med 2012,9,310","journal-title":"J Sex Med"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1055\/s-0031-1297968","volume":"120","author":"Chen Y-H.","year":"2012","unstructured":"Chen Y-H.; Feng B.; Chen Z-W.; Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases: a meta-analysis. Exp Clin Endocrinol Diabetes 2012,120(2),116-120","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s00125-007-0719-8","volume":"50","author":"Van Linthout S.","year":"2007","unstructured":"Van Linthout S.; Riad A.; Dhayat N.; Spillmann F.; Du J.; Dhayat S.; Westermann D.; Hilfiker-Kleiner D.; Noutsias M.; Laufs U.; Schultheiss H.P.; Tsch\u00f6pe C.; Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia 2007,50(9),1977-1986","journal-title":"Diabetologia"},{"key":"ref=88","first-page":"89","volume":"124","author":"Dai Q.M.","year":"2011","unstructured":"Dai Q.M.; Lu J.; Liu N.F.; Fluvastatin attenuates myocardial interstitial fibrosis and cardiac dysfunction in diabetic rats by inhibiting over-expression of connective tissue growth factor. Chin Med J (Engl) 2011,124(1),89-94","journal-title":"Chin Med J (Engl)"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/hrt.2010.208751","volume":"97","author":"Gao D.","year":"2011","unstructured":"Gao D.; Ning N.; Niu X.; Hao G.; Meng Z.; Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011,97(4),278-286","journal-title":"Heart"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3904\/kjim.2016.208","volume":"32","author":"Lee W.S.","year":"2017","unstructured":"Lee W.S.; Kim J.; Diabetic cardiomyopathy: where we are and where we are going. Korean J Intern Med 2017,32(3),404-421","journal-title":"Korean J Intern Med"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s00395-013-0358-9","volume":"108","author":"Nickel A.","year":"2013","unstructured":"Nickel A.; L\u00f6ffler J.; Maack C.; Myocardial energetics in heart failure. Basic Res Cardiol 2013,108(4),358","journal-title":"Basic Res Cardiol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/ejcts\/ezu452","volume":"48","author":"Senanayake E.L.","year":"2015","unstructured":"Senanayake E.L.; Howell N.J.; Ranasinghe A.M.; Drury N.E.; Freemantle N.; Frenneaux M.; Multicentre double-blind randomized controlled trial of perhexiline as a metabolic modulator to augment myocardial protection in patients with left ventricular hypertrophy undergoing cardiac surgery. Eur J Cardiothorac Surg 2015,48(3),354-362","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10741-013-9379-6","volume":"19","author":"Xu Y.J.","year":"2014","unstructured":"Xu Y.J.; Tappia P.S.; Neki N.S.; Dhalla N.S.; Prevention of diabetes-induced cardiovascular complications upon treatment with antioxidants. Heart Fail Rev 2014,19(1),113-121","journal-title":"Heart Fail Rev"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/bph.12461","volume":"171","author":"Szeto H.H.","year":"2014","unstructured":"Szeto H.H.; First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol 2014,171(8),2029-2050","journal-title":"Br J Pharmacol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1007\/s00125-012-2495-3","volume":"55","author":"Huynh K.","year":"2012","unstructured":"Huynh K.; Kiriazis H.; Du X.J.; Love J.E.; Jandeleit-Dahm K.A.; Forbes J.M.; McMullen J.R.; Ritchie R.H.; Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db\/db mouse model of type 2 diabetes. Diabetologia 2012,55(5),1544-1553","journal-title":"Diabetologia"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jchf.2014.06.008","volume":"2","author":"Mortensen S.A.","year":"2014","unstructured":"Mortensen S.A.; Rosenfeldt F.; Kumar A.; Dolliner P.; Filipiak K.J.; Pella D.; Alehagen U.; Steurer G.; Littarru G.P.; The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail 2014,2(6),641-649","journal-title":"JACC Heart Fail"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.pharmthera.2014.01.003","volume":"142","author":"Huynh K.","year":"2014","unstructured":"Huynh K.; Bernardo B.C.; McMullen J.R.; Ritchie R.H.; Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther 2014,142(3),375-415","journal-title":"Pharmacol Ther"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrd796","volume":"1","author":"Salvemini D.","year":"2002","unstructured":"Salvemini D.; Riley D.P.; Cuzzocrea S.; SOD mimetics are coming of age. Nat Rev Drug Discov 2002,1(5),367-374","journal-title":"Nat Rev Drug Discov"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.2337\/diabetes.53.5.1336","volume":"53","author":"Ye G.","year":"2004","unstructured":"Ye G.; Metreveli N.S.; Donthi R.V.; Xia S.; Xu M.; Carlson E.C.; Epstein P.N.; Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 2004,53(5),1336-1343","journal-title":"Diabetes"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nrendo.2009.48","volume":"5","author":"Lovshin J.A.","year":"2009","unstructured":"Lovshin J.A.; Drucker D.J.; Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009,5(5),262-269","journal-title":"Nat Rev Endocrinol"},{"key":"ref=101","author":"Shaikh S.","unstructured":"Shaikh S.; Ahmad S.S.; Ansari M.A.; Shakil S.; Rizvi S.M.D.; Shakil S.; Available at: (Accessed 2014)"},{"key":"ref=102","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.28467","author":"Yaribeygi H.","year":"2019","unstructured":"Yaribeygi H.; Atkin S.L.; Sahebkar A.; Natural compounds with DPP-4 inhibitory effects: Implications for the treatment of diabetes. J Cell Biochem 2019","journal-title":"J Cell Biochem"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/0748233711413799","volume":"28","author":"Kang K.A.","year":"2012","unstructured":"Kang K.A.; Zhang R.; Piao M.J.; Chae S.; Kim H.S.; Park J.H.; Jung K.S.; Hyun J.W.; Baicalein inhibits oxidative stress-induced cellular damage via antioxidant effects. Toxicol Ind Health 2012,28(5),412-421","journal-title":"Toxicol Ind Health"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/nu11030530","volume":"11","author":"Fang J-Y.","year":"2019","unstructured":"Fang J-Y.; Lin C-H.; Huang T-H.; Chuang S-Y.; In vivo rodent models of type 2 diabetes and their usefulness for evaluating flavonoid bioactivity. Nutrients 2019,11(3),530","journal-title":"Nutrients"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3892\/ijmm.2012.1083","volume":"30","author":"Cheng Y.","year":"2012","unstructured":"Cheng Y.; Guo S.; Liu G.; Feng Y.; Yan B.; Yu J.; Feng K.; Li Z.; Transplantation of bone marrow-derived endothelial progenitor cells attenuates myocardial interstitial fibrosis and cardiac dysfunction in streptozotocin-induced diabetic rats. Int J Mol Med 2012,30(4),870-876","journal-title":"Int J Mol Med"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1161\/CIRCRESAHA.110.239111","volume":"108","author":"Katare R.","year":"2011","unstructured":"Katare R.; Caporali A.; Zentilin L.; Avolio E.; Sala-Newby G.; Oikawa A.; Cesselli D.; Beltrami A.P.; Giacca M.; Emanueli C.; Madeddu P.; Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling. Circ Res 2011,108(10),1238-1251","journal-title":"Circ Res"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2337\/db11-0952","volume":"61","author":"Greco S.","year":"2012","unstructured":"Greco S.; Fasanaro P.; Castelvecchio S.; D\u2019Alessandra Y.; Arcelli D.; Di Donato M.; Malavazos A.; Capogrossi M.C.; Menicanti L.; Martelli F.; MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes 2012,61(6),1633-1641","journal-title":"Diabetes"},{"key":"ref=108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041574","volume":"7","author":"Chen H.","year":"2012","unstructured":"Chen H.; Untiveros G.M.; McKee L.A.; Perez J.; Li J.; Antin P.B.; Konhilas J.P.; Micro-RNA-195 and -451 regulate the LKB1\/AMPK signaling axis by targeting MO25. PLoS One 2012,7(7)","journal-title":"PLoS One"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.2337\/diabetes.46.10.1563","volume":"46","author":"Kubisch H.M.","year":"1997","unstructured":"Kubisch H.M.; Wang J.; Bray T.M.; Phillips J.P.; Targeted overexpression of Cu\/Zn superoxide dismutase protects pancreatic \u03b2-cells against oxidative stress. Diabetes 1997,46(10),1563-1566","journal-title":"Diabetes"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"798","DOI":"10.2337\/diabetes.55.03.06.db05-1039","volume":"55","author":"Shen X.","year":"2006","unstructured":"Shen X.; Zheng S.; Metreveli N.S.; Epstein P.N.; Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006,55(3),798-805","journal-title":"Diabetes"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.lfs.2007.07.029","volume":"81","author":"Turdi S.","year":"2007","unstructured":"Turdi S.; Li Q.; Lopez F.L.; Ren J.; Catalase alleviates cardiomyocyte dysfunction in diabetes: role of Akt, Forkhead transcriptional factor and silent information regulator 2. Life Sci 2007,81(11),895-905","journal-title":"Life Sci"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1210\/en.2009-0708","volume":"150","author":"Harmon J.S.","year":"2009","unstructured":"Harmon J.S.; Bogdani M.; Parazzoli S.D.; Mak S.S.; Oseid E.A.; Berghmans M.; Leboeuf R.C.; Robertson R.P.; \u03b2-cell-specific overexpression of glutathione peroxidase preserves intranuclear MafA and reverses diabetes in db\/db mice. Endocrinology 2009,150(11),4855-4862","journal-title":"Endocrinology"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"H2237","DOI":"10.1152\/ajpheart.00427.2006","volume":"291","author":"Matsushima S.","year":"2006","unstructured":"Matsushima S.; Kinugawa S.; Ide T.; Matsusaka H.; Inoue N.; Ohta Y.; Yokota T.; Sunagawa K.; Tsutsui H.; Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Am J Physiol Heart Circ Physiol 2006,291(5),H2237-H2245","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.yjmcc.2010.11.002","volume":"50","author":"Adluri R.S.","year":"2011","unstructured":"Adluri R.S.; Thirunavukkarasu M.; Zhan L.; Akita Y.; Samuel S.M.; Otani H.; Ho Y.S.; Maulik G.; Maulik N.; Thioredoxin 1 enhances neovascularization and reduces ventricular remodeling during chronic myocardial infarction: a study using thioredoxin 1 transgenic mice. J Mol Cell Cardiol 2011,50(1),239-247","journal-title":"J Mol Cell Cardiol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1172\/JCI200317700","volume":"112","author":"Yamamoto M.","year":"2003","unstructured":"Yamamoto M.; Yang G.; Hong C.; Liu J.; Holle E.; Yu X.; Wagner T.; Vatner S.F.; Sadoshima J.; Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest 2003,112(9),1395-1406","journal-title":"J Clin Invest"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.freeradbiomed.2013.02.021","volume":"60","author":"Huynh K.","year":"2013","unstructured":"Huynh K.; Kiriazis H.; Du X.J.; Love J.E.; Gray S.P.; Jandeleit-Dahm K.A.; McMullen J.R.; Ritchie R.H.; Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice. Free Radic Biol Med 2013,60,307-317","journal-title":"Free Radic Biol Med"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/ATVBAHA.109.201988","volume":"30","author":"Lin R.C.","year":"2010","unstructured":"Lin R.C.; Weeks K.L.; Gao X.M.; Williams R.B.; Bernardo B.C.; Kiriazis H.; Matthews V.B.; Woodcock E.A.; Bouwman R.D.; Mollica J.P.; Speirs H.J.; Dawes I.W.; Daly R.J.; Shioi T.; Izumo S.; Febbraio M.A.; Du X.J.; McMullen J.R.; PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA. Arterioscler Thromb Vasc Biol 2010,30(4),724-732","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","volume":"175","author":"Pretorius L.","year":"2009","unstructured":"Pretorius L.; Du X.J.; Woodcock E.A.; Kiriazis H.; Lin R.C.; Marasco S.; Medcalf R.L.; Ming Z.; Head G.A.; Tan J.W.; Cemerlang N.; Sadoshima J.; Shioi T.; Izumo S.; Lukoshkova E.V.; Dart A.M.; Jennings G.L.; McMullen J.R.; Reduced phosphoinositide 3-kinase (p110\u03b1) activation increases the susceptibility to atrial fibrillation. Am J Pathol 2009,175(3),998-1009","journal-title":"Am J Pathol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1007\/s00125-012-2720-0","volume":"55","author":"Ritchie R.H.","year":"2012","unstructured":"Ritchie R.H.; Love J.E.; Huynh K.; Bernardo B.C.; Henstridge D.C.; Kiriazis H.; Tham Y.K.; Sapra G.; Qin C.; Cemerlang N.; Boey E.J.; Jandeleit-Dahm K.; Du X.J.; McMullen J.R.; Enhanced phosphoinositide 3-kinase(p110\u03b1) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes. Diabetologia 2012,55(12),3369-3381","journal-title":"Diabetologia"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nrd3871","volume":"11","author":"Mochly-Rosen D.","year":"2012","unstructured":"Mochly-Rosen D.; Das K.; Grimes K.V.; Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov 2012,11(12),937-957","journal-title":"Nat Rev Drug Discov"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1517\/14740338.5.6.835","volume":"5","author":"McGill J.B.","year":"2006","unstructured":"McGill J.B.; King G.L.; Berg P.H.; Price K.L.; Kles K.A.; Bastyr E.J.; Hyslop D.L.; Clinical safety of the selective PKC-\u03b2 inhibitor, ruboxistaurin. Expert Opin Drug Saf 2006,5(6),835-845","journal-title":"Expert Opin Drug Saf"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1097\/IAE.0b013e3182111669","volume":"31","author":"Aiello L.P.","year":"2011","unstructured":"Aiello L.P.; Vignati L.; Sheetz M.J.; Zhi X.; Girach A.; Davis M.D.; Wolka A.M.; Shahri N.; Milton R.C.; Oral protein kinase c \u03b2 inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the protein kinase C \u03b2 inhibitor-diabetic retinopathy study and the protein kinase C \u03b2 inhibitor-diabetic retinopathy study 2. Retina 2011,31(10),2084-2094","journal-title":"Retina"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.111.071886","volume":"126","author":"Denise Martin E.","year":"2012","unstructured":"Denise Martin E.; De Nicola G.F.; Marber M.S.; New therapeutic targets in cardiology: p38 alpha mitogen-activated protein kinase for ischemic heart disease. Circulation 2012,126(3),357-368","journal-title":"Circulation"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1161\/CIRCRESAHA.109.210088","volume":"106","author":"Meloni M.","year":"2010","unstructured":"Meloni M.; Caporali A.; Graiani G.; Lagrasta C.; Katare R.; Van Linthout S.; Spillmann F.; Campesi I.; Madeddu P.; Quaini F.; Emanueli C.; Nerve growth factor promotes cardiac repair following myocardial infarction. Circ Res 2010,106(7),1275-1284","journal-title":"Circ Res"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2337\/db11-0763","volume":"61","author":"Meloni M.","year":"2012","unstructured":"Meloni M.; Descamps B.; Caporali A.; Zentilin L.; Floris I.; Giacca M.; Emanueli C.; Nerve growth factor gene therapy using adeno-associated viral vectors prevents cardiomyopathy in type 1 diabetic mice. Diabetes 2012,61(1),229-240","journal-title":"Diabetes"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1253\/circj.CJ-13-0841","volume":"78","author":"Hu S.","year":"2014","unstructured":"Hu S.; Yan G.; Xu H.; He W.; Liu Z.; Ma G.; Hypoxic preconditioning increases survival of cardiac progenitor cells via the pim-1 kinase-mediated anti-apoptotic effect. Circ J 2014,78(3),724-731","journal-title":"Circ J"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/nm1671","volume":"13","author":"Muraski J.A.","year":"2007","unstructured":"Muraski J.A.; Rota M.; Misao Y.; Fransioli J.; Cottage C.; Gude N.; Esposito G.; Delucchi F.; Arcarese M.; Alvarez R.; Siddiqi S.; Emmanuel G.N.; Wu W.; Fischer K.; Martindale J.J.; Glembotski C.C.; Leri A.; Kajstura J.; Magnuson N.; Berns A.; Beretta R.M.; Houser S.R.; Schaefer E.M.; Anversa P.; Sussman M.A.; Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med 2007,13(12),1467-1475","journal-title":"Nat Med"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1161\/CIRCHEARTFAILURE.112.966622","volume":"5","author":"Weeks K.L.","year":"2012","unstructured":"Weeks K.L.; Gao X.; Du X.J.; Boey E.J.; Matsumoto A.; Bernardo B.C.; Kiriazis H.; Cemerlang N.; Tan J.W.; Tham Y.K.; Franke T.F.; Qian H.; Bogoyevitch M.A.; Woodcock E.A.; Febbraio M.A.; Gregorevic P.; McMullen J.R.; Phosphoinositide 3-kinase p110\u03b1 is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ Heart Fail 2012,5(4),523-534","journal-title":"Circ Heart Fail"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"Rupaimoole R.","year":"2017","unstructured":"Rupaimoole R.; Slack F.J.; MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 2017,16(3),203-222","journal-title":"Nat Rev Drug Discov"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/cvr\/cvw174","volume":"111","author":"Navickas R.","year":"2016","unstructured":"Navickas R.; Gal D.; Laucevi\u010dius A.; Taparauskait\u0117 A.; Zdanyt\u0117 M.; Holvoet P.; Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovasc Res 2016,111(4),322-337","journal-title":"Cardiovasc Res"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1161\/CIRCRESAHA.111.247916","volume":"110","author":"Rooij E.v.","year":"2012","unstructured":"Rooij E.v.; Purcell A.L.; Levin A.A.; Developing microRNA therapeutics. Circ Res 2012,110(3),496-507","journal-title":"Circ Res"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1161\/ATVBAHA.112.300920","volume":"33","author":"Weber C.","year":"2013","unstructured":"Weber C.; MicroRNAs: from basic mechanisms to clinical application in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2013,33(2),168-169","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Endocrine, Metabolic &amp; Immune Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/184453","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.eurekaselect.com\/184453\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/eurekaselect.com\/article\/download\/184453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T04:20:51Z","timestamp":1696479651000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/184453\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":132,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871530320666200731174724","relation":{},"ISSN":["1871-5303"],"issn-type":[{"value":"1871-5303","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}